Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Osteoarthritis

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

August 1, 2018

Study Completion Date

September 30, 2018

Conditions
Chronic Knee Joint Osteoarthritis
Interventions
OTHER

Saphenous nerve block group

Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg

OTHER

Platelet rich plasma group

Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma

Trial Locations (1)

050

Mansoura University Hospitals, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT03326544 - Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Osteoarthritis | Biotech Hunter | Biotech Hunter